AI Analysis
Summary
Innorna received a Prix Galien USA Best Startup Award nomination for 2026 based on its mRNA-LNP platform innovation and clinical pipeline. The company's lead program IN026, an mRNA therapy for refractory gout, received FDA IND clearance in March 2026.
Clinical Trial Data
Phase
IND
Outcome Details
Prix Galien USA Best Startup Award nomination
Importance:4/10
Sentiment:
0.60
mRNA-LNP platformclinical stageIN026goutIND approvalaward nomination
Read the original article
Published by PR Newswire Clinical Trials on August 13, 2026 3:17 PM